Table I.
Demographics and Baseline Characteristicsa
| BMI, kg/m 2 | Placebo | Nebivolol 1.25 mg | Nebivolol 2.5 mg | Nebivolol 5 mg | Nebivolol 10 mg | Nebivolol 20 mg | Nebivolol 30/40 mg | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <30 (n=133) | ≥30 (n=92) | <30 (n=43) | ≥30 (n=40) | <30 (n=71) | ≥30 (n=60) | <30 (n=269) | ≥30 (n=189) | <30 (n=273) | ≥30 (n=188) | <30 (n=263) | ≥30 (n=196) | <30 (n=104) | ≥30 (n=113) | |
| Age, y | 54±11 | 51±9 | 57±11 | 54±12 | 53±12 | 51±11 | 55±12 | 52±10 | 55±12 | 52±10 | 54±11 | 53±11 | 55±13 | 52±11 |
| Male sex | 61 (54.0) | 47 (51.1) | 25 (58.1) | 21 (52.5) | 47 (66.2) | 32 (53.3) | 149 (55.4) | 99 (52.4) | 154 (56.4) | 92 (48.9) | 141 (53.6) | 103 (52.3) | 55 (52.9) | 59 (52.2) |
| Race | ||||||||||||||
| Caucasian | 80 (70.8) | 54 (58.7) | 35 (81.4) | 35 (87.5) | 39 (54.9) | 30 (50.0) | 206 (76.6) | 143 (75.7) | 210 (76.9) | 136 (72.3) | 203 (77.2) | 45 (73.6) | 69 (66.3) | 69 (61.1) |
| Non‐ Caucasian | 33 (29.2) | 38 (41.3) | 8 (18.6) | 5 (12.5) | 32 (45.1) | 30 (50.0) | 63 (23.4) | 46 (24.3) | 63 (23.1) | 52 (27.7) | 60 (22.8) | 52 (26.4) | 35 (33.7) | 44 (38.9) |
| Black | 33 (100.0) | 38 (100.0) | 7 (87.5) | 5 (100.0) | 32 (100.0) | 30 (100.0) | 59 (93.7) | 45 (97.8) | 55 (87.3) | 52 (100.0) | 55 (91.7) | 50 (96.2) | 33 (94.3) | 43 (97.7) |
| Asian | 0 | 0 | 1 (12.5) | 0 | 0 | 0 | 4 (6.3) | 1 (2.2) | 3 (4.8) | 0 | 3 (5.0) | 2 (3.8) | 0 | 1 (2.3) |
| Weight, kg | 75.6±12.4 | 98.1±11.3 | 76.7±12.4 | 95.2±12.6 | 78.3±12.5 | 97.8±11.2 | 77.2±12.4 | 96.0±12.1 | 76.8±12.2 | 96.2±13.2 | 77.0±12.4 | 95.5±11.9 | 77.0±12.7 | 97.5±12.1 |
Values are expressed as mean ± standard deviation or No. (%). aPatients with a body mass index (BMI) ≥35 kg/m2 were excluded.